Dare Bioscience

Dare Bioscience OCF Margin

The Operating Cash Flow Margin of Dare Bioscience (DARE) as of Oct 30, 2026 is -959.61 %. In the previous year, Operating Cash Flow Margin was 55,133.35 % — a change of -101.74% (lower).

OCF Margin

-959.61 %

YoY

-101.74%

Last updated:

Operating Cash Flow Margin of Dare Bioscience is 2025 -959.61 % . Operating Cash Flow Margin of Dare Bioscience was 2024 55,133.35 % . It decreases by -101.74% lower compared to the previous year.

The Dare Bioscience OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2014
-23,826.25 USD
Jan 1, 2016
-4,378.07 USD
Jan 1, 2021
-287.64 USD
Jan 1, 2022
-180.88 USD
Jan 1, 2023
-1,383.84 USD
Jan 1, 2024
55,133.35 USD
Jan 1, 2025
-959.61 USD
The Dare Bioscience OCF Margin history
YEAROCF MarginYoY
-959.61 %-101.74%
55,133.35 %-4,084.08%
-1,383.84 %+665.04%
-180.88 %-37.11%
-287.64 %-93.43%
-4,378.07 %-81.63%
-23,826.25 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

Operating Cash Flow Margin of Dare Bioscience is -959.61 % in 2025.

Operating Cash Flow Margin of Dare Bioscience changed from 55,133.35 % to -959.61 %, representing a -101.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Dare Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Dare Bioscience

All Key Metrics — Dare Bioscience